Last reviewed · How we verify
NCT03371862: SLIPS
Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)
Phase 2 trial testing Liraglutide Pen Injector [Victoza] in Short Bowel Syndrome. Withdrawn.
6 August 2020
Quick facts
| Lead sponsor | Imperial College London |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 20 October 2017 |
| Primary completion | 6 August 2020 |
| Estimated completion | 30 September 2020 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Liraglutide Pen Injector [Victoza] — full drug profile →
Conditions studied
- Short Bowel Syndrome — all drugs for Short Bowel Syndrome →
Sponsor
Imperial College London
Who can join
18 and older, any sex, with Short Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pilot study looking at the effect on Liraglutide in the reduction of parenteral support in patients with short bowel.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03371862
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Liraglutide Pen Injector [Victoza]
Trials testing the same drug.
- NCT03260881 — Liraglutide Effects on Epicardial Fat Inflammatory Genes · Phase 4 · completed
Other recruiting trials for Short Bowel Syndrome
Currently open trials in the same condition.
- NCT07197944 — Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS · Phase 3 · recruiting
- NCT05535361 — A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in A · NA · recruiting
- NCT06973304 — A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome · Phase 3 · recruiting
- NCT06326645 — Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome · EARLY_PHASE1 · recruiting
- NCT06771505 — SBS DISK- Creation of a Quality of Life Tool for Short Bowel Patients Compared With a Validated Quality of Life Question · recruiting
Other Imperial College London trials
Trials by the same sponsor.
- NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
- NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
- NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
- NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
- NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03371862 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Imperial College London
- Last refreshed: 14 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03371862.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing